AUIC in Humans: A Fact-Based Discussion

Schentag JJ Meagher AK Forrest A Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003;37:1478–88. DOI 10.1345/aph.1C419.

Amsden GW Ballow CH Schentag JJ Population pharmacokinetic methods to optimise antibiotic effects. Drug Invest 1993;5:256–68.

Preston SL Drusano GL Berman AL Fowler CL Chow AT Dornseif B Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125–9.

Forrest A Nix DE Ballow CH Goss TF Birmingham MC Schentag JJ Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073–81.

Schentag JJ Vari AJ Winslade NE Swanson DJ Smith IL Simons GW Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med 1985;78:34–41.

Smith PF Ballow CH Booker BM Forrest A Schentag JJ Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;23:1231–44.

Garcia I Pascual A Ballesta S Perea EJ Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells. Int J Antimicrob Agents 2000;15:201–5.

Braga PC Dal Sasso M Bovio C Zavaroni E Fonti E Effects of gatifloxacin on phagocytosis, intracellular killing and oxidant radical production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 2002;19:183–7.

Kiem S Craig WA Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae (SP) (abstract A-492). In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.

Drusano GL Preston SL Owens RC Jr Ambrose PG Fluoroquinolone pharmacodynamics. Clin Infect Dis 2001;33:2091–2.

Schentag JJ Gilliland KK Paladino JA What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(supple 1):S39–46.

Ambrose PG Grasela DM Grasela TH Passarell J Mayer H Pierce PF Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793–7.

Forrest A Chodosh S Amantea MA Collins DA Schentag JJ Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(suppl A):45–57.

Jumbe NL Louie A Liu W Deziel M Miller MH Drusano GL Pharmacodynamics of levofloxacin with different organisms: one size does not fit all (abstract 291). In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000.

Craig WA Andes DR Correlation of the magnitude of the AUC₂₄/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model (abstract 289). In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000.

Schentag JJ Antibiotic dosing - does one size fit all? JAMA 1998;279:159–60.

American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54.

Thomas JK Forrest A Bhavnani SM Hyatt JM Cheng A Ballow CH Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521–7.

Mouton JW Why the AUC/MIC ratio should not be used to predict the effects of β-lactams. Clin Infect Dis 2002;35:209–10.